Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its ...

This time, the FDA took issue with how the ad positioned Ozempic as superior to other GLP-1s, taking aim at small details from comedic devices to the color of shirts.

Novo Nordisk (NVO) stock is in focus as the firm gets FDA scrutiny over an Ozempic TV ad, the second warning it received for GLP-1 ad claims in weeks. Read more here.

The study analysed two years of search ads linked to Ozempic.com. An estimated $7.5m was spent on 15,000+ keywords, ...

Hannay: It depends what you mean by “struggling.” The company has been enormously successful in recent years because of ...

The U.S. Food and Drug ⁠Administration ⁠has warned Novo Nordisk ⁠over a consumer ad for its blockbuster diabetes drug, ...

Roche eyes a significant share in the weight loss market, competing against Novo Nordisk. Aspen Pharmacare anticipates a rebound in profits despite an earlier drop. Elevance Health faces enrollment ...

FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance ...

The U.S. Food and Drug Administration (FDA) has issued warning letters to 30 telehealth companies citing false or misleading claims about compounded GLP-1 weight-loss products on their websites. The ...

GLP-1 weight loss medications like Ozempic, Mounjaro, and Wegovy have exploded in popularity after countless testimonies from celebrities and regular people alike, with worldwide Google searches for ...

Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of ...